Globus Medical shares are down roughly 3% in the latest session as the market continues to re-rate the name around its 2026 setup: decelerating top-line growth versus the prior year, with the bull case leaning more heavily on margin expansion and synergy capture. After the company’s recent full-year update, investors have focused on execution risk and the quality/timing of revenue conversion, rather than just the headline guidance ranges. (massdevice.com)

In its most recent update tied to full-year results, Globus reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised non-GAAP diluted EPS guidance to $4.40–$4.50, alongside expectations for gross-margin expansion. While the EPS lift helps, the revenue guide implies a noticeably slower growth profile than the prior year, increasing sensitivity to any signs of spine-market share pressure, sales force productivity issues, or integration-related disruption. (massdevice.com)

With no clear, company-specific shock headline dominating today, the move looks driven by positioning and sentiment around the 2026 deceleration narrative and the ongoing digestion of acquisition-related complexity. In this setup, incremental selling can be triggered by any renewed emphasis on execution risk in the spine franchise, or by investors taking gains/derisking after the stock’s earlier swings around results and guidance. (massdevice.com)

Key watch items include any additional commentary on spine demand trends, revenue recognition timing (cash sales vs. placements/leases), and whether margin expansion stays on track as integration progresses. The next major catalyst is the next earnings report and any interim updates that refine 2026 expectations or indicate whether growth is re-accelerating. (tipranks.com)